Pangen Wins KDCA Contract for SFTS Antibody Non-clinical Sample Production Worth 2.75 Billion KRW, Boosting R&D and Future Revenue
Pangen has secured a research service contract with the Korea Disease Control and Prevention Agency KDCA National Institute of Health for the advancement and evaluation of non-clinical sample production system for SFTS therapeutic antibody.
The contract value is approximately 2.745 billion KRW, representing 20.46% of the company's 2025 annual revenue of 13.417 billion KRW.
The contract period runs from June 22, 2026 to December 31, 2028, with an advance payment of about 757 million KRW 70% of the first year amount due within 30 days of signing.
The counterparty is a national government agency with extremely high creditworthiness, minimizing default risk and ensuring stable cash inflows.
This contract validates Pangen's antibody production process optimization and non-clinical sample manufacturing capabilities, enhancing future contract win potential in related fields.
No equity-related capital changes or dividend policy disclosures were included in this filing.
[AI Summary]This government research service contract enables Pangen to achieve revenue growth and technological advancement without shareholder dilution. The contract size exceeding 20% of sales and favorable advance payment terms improve cash flow, while the long-term potential to enter the SFTS therapy market supports shareholder value creation.